Is it necessary to continue taking Sotorasiib for a long time?

Sotorasib is a targeted drug mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. As an oral drug, sotorasiib can effectively inhibit the growth of KRAS G12C mutated tumor cells. The patient's specific treatment plan will vary based on individual circumstances and tumor response as to whether long-term continued use is required.

Sotorasiib usually needs to be taken long-term during treatment until the condition is stable or intolerable side effects occur. According to clinical research data, patients usually need to continue taking the drug for a longer period of time to achieve optimal efficacy after receiving sotorasiib treatment. Most patients will experience significant tumor shrinkage or disease stabilization within a few months of drug treatment. Therefore, continued use is to maintain the effect and prevent tumor recurrence.

Long-term use of sotoracib may also cause certain side effects, the most common of which include diarrhea, fatigue, and loss of appetite. These side effects are generally mild, but for some patients, managing side effects can be a challenge during treatment. Therefore, doctors usually adjust the dosage of the drug based on the patient's tolerance, or combine it with other treatments to ensure that the patient continues to get the maximum therapeutic effect.

In general, the duration of administration of sotorasib and whether long-term continued administration is required will be individually adjusted based on the patient's response. In some patients, the drug may need to be discontinued or other treatment options may need to be switched if the tumor becomes resistant or if treatment becomes less effective. For most patients, long-term continuous administration of sotorasib is necessary to maximize control of tumor growth and metastasis. Patients should communicate with their doctors regularly during treatment to ensure the rationality of the treatment plan and the sustainability of the efficacy.

Reference materials:https://www.lumakras.com/